A clinical trial of a drug used for treating lung cancer has revealed “a remarkable advancement”.
As per the trial, the new anti-cancer drug has unveiled that 60% of patients are still alive. Moreover, the cancer did not spread to any other part of the body, according to Interesting Engineering.
The protein anaplastic lymphoma kinase (ALK) plays a prominent role in regulating cell growth. It is produced as a result of the ALK gene. This gene can be rearranged in certain cancers including non-small cell lung cancer (NSCLC).
Among these, ALK-positive tumors occur in approximately 3% to 5% of cases among these cancers.
The trial’s results revealed that Lorlatinib is a third-generation ALK inhibitor. Used as the standard first-line treatment for patients with ALK-positive NSCLC, it is the latest in a class of drugs.
Led by the Peter MacCallum Cancer Center in Melbourne, Australia, a recent international clinical trial evaluated the drug’s impact on long-term disease progression in patients with advanced ALK-positive NSCLC.
Peter Mac’s Professor Ben Solomon, the study’s lead and corresponding author, said in an interview with The Guardian: “To our knowledge, these results are unprecedented.”
Chikungunya spreads through bites of infected "Aedes aegypti" and "Aedes albopictus" mosquitoes
Researchers emphasise that new study shows an association between poor sleep and faster brain ageing
Research finds standing to likely increase individual’s risk for circulatory issues
Met Office directs stakeholders to take pre-emptive measures to address prevailing dengue situation in country
Psychologist reveals stress during challenges can give human body fuel to address demands it faces, making it...
As many as 30 cases of pneumonia being reported daily, reveals emergency in charge at NICH
